Intralesional Triamcinolone

Phase 3Small molecule

CCentro Dermatológico Dr. Ladislao de la Pascua

Intralesional Triamcinolone is one of 28 small molecule programs targeting Keloid. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

KeloidActive, not recruiting

KeloidPhase 3

Active, not recruiting

Competition

Competitive Landscape

63 competitors in Keloid

#DrugCompanyPhaseTrials

Blenoxane

Bristol-Myers Squibb

Approved

1 2

Kenalog

BBassett Healthcare

Approved

4 3

Botox

RRevance Therapeutics, Inc.

Approved

2 4

Calan

VVal Adams

Approved

2 5

Rapamune

PPrism Pharmaceuticals

Approved

—6

Aldara

BBausch Health Americas, Inc.

Approved

—7

Esbriet

LLegacy Health System

Phase 3

1 8

Nexavar

Bayer

Phase 2

1 9

Opzelura

Pfizer

Phase 2

1 10

Avastin

BBio-Thera Solutions

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Keloid1 trial

Efficacy of Intralesional Triamcinolone and 8% Topical Pirfenidone for Treatment of Keloid Scars

Unknown status·CCentro Dermatológico Dr. Ladislao de la Pascua·Phase 3·NCT02823236·102 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intralesional Triamcinolone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intralesional Triamcinolone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intralesional Triamcinolone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centro Dermatológico Dr. Ladislao de la Pascua company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCentro Dermatológico Dr. Ladislao de la Pascua

Intralesional Triamcinolone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Keloid1 trial

References

Drug Info

Quick Facts

Related News